MedTrace Logo

NPC-12G Gel 0.2% Sirolimus PK Bridging Study

NCT03972462 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2020-03-06

No results posted yet for this study

Summary

This study is designed to describe the relative systemic bioavailability of topical and oral sirolimus formulations.

Conditions

  • Bioavailability Study

Interventions

DRUG

NPC-12G Gel 0.2%

Period 1

DRUG

Rapamune® 2 mg tablet

Period 2

Sponsors & Collaborators

  • Nobelpharma

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-05-31
Primary Completion
2019-06-17
Completion
2019-06-17
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03972462 on ClinicalTrials.gov